

Date: 18th April, 2016

To,
Mr. Avishkar Naik
Chief Manager – Surveillance
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

Dear Sir/Madam,

Sub.: Confirmation/Information on published news

Ref.: NSE/CM/Surveillance/6221 dated 18th April, 2016

We refer to your cited letter and the captioned subject. This is to inform that the Formulations facility of the Company at Panelav, Halol was inspected by the US FDA from 21st to 25th March, 2016. The Company had received four observations which are being addressed by our regulatory and quality team.

We wish to further inform you that, to the best of our knowledge and understanding, the above events or informations may not have any bearing on the operations / performance of the Company.

This is for the kind information of the Stock Exchange and Investors.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

A. K. Desai

Ajay Kumar Desai
Vice President – Finance & Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
www.alembic-india.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123